GlassScriptPhysician profile
John A Traynham
NPI 1073562500
$3,530.77
in general payments reported to CMS, 2019-2025
26 companies · $342 in 2025
The $342 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $306 · 2021: $621 · 2022: $359 · 2023: $632 · 2024: $873 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,846.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $601.93 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $418.78 | 2019-2025 | |
| Corium, LLC | $397.07 | 2021-2025 | Azstarys |
| Glaxosmithkline, LLC. | $316.46 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Ironshore Pharmaceuticals INC. | $274.98 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $251.24 | 2019-2021 | |
| Neos Therapeutics, LP | $231.90 | 2019-2021 | |
| Adlon Therapeutics L.P. | $178.71 | 2019-2021 | |
| Seqirus USA INC | $138.17 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $128.68 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $96.61 | 2024-2025 | |
| Sobi, INC | $87.35 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $81.27 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $48.73 | 2024 | Ycanth |
| Merck Sharp & Dohme LLC | $47.18 | 2023-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $44.44 | 2019 | |
| Noven Therapeutics, LLC | $42.47 | 2025 | Xelstrym |
| Sanofi Pasteur INC. | $42.43 | 2022-2023 | |
| Travere Therapeutics, INC. | $23.79 | 2023 | Cholbam |
| Genentech USA, INC. | $20.74 | 2019 | |
| Biomarin Pharmaceutical INC. | $16.69 | 2023 | Voxzogo 1.2mg |
| Ultragenyx Pharmaceutical INC. | $15.25 | 2022 | |
| Biogen, INC. | $13.47 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.43 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Traynham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.